Vaccitech Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vaccitech stock.
View analyst ratings for Vaccitech or view top-rated stocks.

Wall Street analysts have given Vaccitech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccitech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vaccitech plc (NASDAQ:VACC) released its quarterly earnings data on Monday, June, 14th. The company reported ($0.96) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.21) by $0.25. The firm earned $0.22 million during the quarter, compared to analyst estimates of $0.10 million.
View Vaccitech's earnings history.

4 brokers have issued twelve-month price targets for Vaccitech's shares. Their forecasts range from $22.00 to $28.00. On average, they expect Vaccitech's stock price to reach $25.00 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts' price targets for Vaccitech or view top-rated stocks among Wall Street analysts.

Some companies that are related to Vaccitech include Nuvation Bio (NUVB), Global Blood Therapeutics (GBT), Myovant Sciences (MYOV), Organogenesis (ORGO), Morphic (MORF), Axsome Therapeutics (AXSM), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Centessa Pharmaceuticals (CNTA), MorphoSys (MOR), Amarin (AMRN), Indivior (INVVY), Deciphera Pharmaceuticals (DCPH), Aurinia Pharmaceuticals (AUPH) and Constellation Pharmaceuticals (CNST).
View all of VACC's competitors.

(VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

Vaccitech's lock-up period expires on Wednesday, October 27th. Vaccitech had issued 6,500,000 shares in its IPO on April 30th. The total size of the offering was $110,500,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Shares of VACC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VACC stock can currently be purchased for approximately $15.07.

Vaccitech has a market capitalization of $517.35 million and generates $4.82 million in revenue each year.

Vaccitech employs 49 workers across the globe.

The official website for Vaccitech is www.vaccitech.co.uk.

Vaccitech is headquartered at THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE.

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company can be reached via phone at 44 1865 818 808 or via email at [email protected]